The Oncology Research Training Program has been in existence for 30 years and was developed with the primary goal of preparing physician-trainees for careers in academic oncology. The rationale for training in oncology research is three fold: (1) Cancer remains the leading cause of morbidity and mortality in the US;(2) There is a need to maintain momentum that has been achieved in our fundamental understanding of carcinogenesis (particularly in the molecular pathogenesis of cancer);and (3) There is a need to translate progress gained in the laboratory to the development of new strategies for the diagnosis, treatment, and prevention of cancer. Research training themes of the Program are based on the investigative interest and expertise of 27 well-established and extramurally-funded faculty members in the Division of Hematology/Oncology in the Department of Internal Medicine and the Comprehensive Cancer Center of the University of Michigan (UMCCC) (which includes faculty with appointments in other clinical and basic science departments). These research training themes in the current application are: (1) Molecular-genetic mechanisms of neoplastic transformation, aberrant signaling, and metastasis, (2) Biomarkers in cancer prevention and therapy;(3) Cancer stem cells;(4) Molecular targets of drug discovery and experimental therapeutics of cancer;and (5) Immunological approaches to cancer therapy. Trainees will be exposed to research opportunities across the spectrum from basic laboratory research to translational and clinical research, with the long-term goal of establishing an academic career in cancer research in one of these areas and being paired with an appropriate mentor. It is expected that trainees selected for this program will spend 2- 3 years in the laboratory or relevant clinical research environment under the direct supervision of a training program faculty mentor and will develop skills in: (1) Identifying testable hypotheses that address important questions in oncology research;(2) Acquiring the necessary technical expertise to test the hypotheses identified;(3) Critically evaluating the data generated;and (4) Developing the necessary skills of written and oral communication to promulgate conclusions made. The majority of trainees will have an MD degree or MD/PhD degrees, 3 years of house officer training in Internal Medicine and a year of clinical subspecialty training in medical oncology/hematology. MD trainees with limited prior research experience will be encouraged to participate in an intensive 3 month postdoctoral research training program (directed and taught by Training Program faculty) to introduce them to important concepts in cellular and molecular biology. The ultimate goal of the program is to prepare trainees for careers in academic oncology as independent faculty members of schools of medicine at research universities.

Public Health Relevance

The goal of the Oncology Research Training Program is to teach MD or MD/PhD candidates cancer specialists-in-training the skills necessary to pursue careers in cancer research so that they can contribute to the development of advances in the prevention, diagnosis, and treatment of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Internal Medicine/Medicine
Schools of Medicine
Ann Arbor
United States
Zip Code
Wang, Lidong; Yang, Huibin; Palmbos, Phillip L et al. (2014) ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells. Cancer Res 74:1778-88
Malek, S N (2013) The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 32:2805-17
Parkin, Brian; Ouillette, Peter; Li, Yifeng et al. (2013) Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 121:369-77
Bradley, Deborah; Rathkopf, Dana; Dunn, Rodney et al. (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Universi Cancer 115:5541-9
Rubenstein, Joel H; Waljee, Akbar K; Jeter, Joanne M et al. (2009) Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 104:2222-32
Chen, Grace; Shaw, Michael H; Kim, Yun-Gi et al. (2009) NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 4:365-98
Chen, Grace Y; Shaw, Michael H; Redondo, Gloria et al. (2008) The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68:10060-7
Bradley, Deborah A; Hussain, Maha (2008) Promising novel cytotoxic agents and combinations in metastatic prostate cancer. Cancer J 14:15-9
Bradley, Deborah A; Dunn, Rodney; Nanus, David et al. (2007) Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 5:460-3
Lee, Kuei C; Bradley, Deborah A; Hussain, Maha et al. (2007) A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9:1003-11

Showing the most recent 10 out of 17 publications